Table 1 Patient characteristics, asthma-related quality of life (AQLQ), atopic dermatitis related quality of life (DLQI), and asthma-related treatment at baseline and after 6 and 12 months omalizumab therapy
Asthma | Asthma + atopic dermatitis | P value | |
|---|---|---|---|
n | 13 | 9 | |
Age (years) | 47.5 ± 14.8 | 38.1 ± 11.3 | 0.127 |
Sex /female) | 10/13 77% | 6/9 67% | 0.394 |
IgE | 212 ± 224 | 3528 ± 2723 | < 0.001 |
FEV1 | 71.5 ± 10,7 | 76.2 ± 7,4 | 0.350 |
Weight in kg | 82.3 ± 22.0 | 76.3 ± 16.1 | 0.472 |
Omalizumab dosage | |||
(mg/2 weeks) | 213 ± 86 | 233 ± 109 | 0.654 |
OCS baseline | 12/13 | 7/9 | 0.394 |
OCS 6 month | 4/13 | 0/9 | 0.003 |
OCS 12 month | 4/13 | 0/9 | 0.003 |
AQlQ baseline | 102 ± 40 | 143 ± 44 | 0.041 |
AQlQ 6 month | 148 ± 48 | 175 ± 40 | 0.041 |
AQlQ 12 month | 152 ± 45 | 170 ± 42 | 0.04 |
DlQI baseline | 19 ± 10 | ||
DlQI 6 month | 7 ± 8 | ||
DlQI 12 moth | 6 ± 6 |